JQKD82 trihydrochloride (Synonyms: JADA82 trihydrochloride; PCK82 trihydrochloride) |
| Katalog-Nr.GC64841 |
JQKD82 (JADA82) Trihydrochlorid ist ein zellgÄngiger und selektiver KDM5-Inhibitor. JQKD82-Trihydrochlorid erhÖht H3K4me3 und kann fÜr die Erforschung des multiplen Myeloms verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
JQKD82 (JADA82) trihydrochloride is a cell-permeable and selective KDM5 inhibitor. JQKD82 trihydrochloride increases H3K4me3 and can be used for the research of multiple myeloma[1].
JQKD82 (0.3 μM; 24 hours) trihydrochloride causes an increase in the global H3K4me3 level of MM.1S cells[1].JQKD82 (0.1-10 μM; day 1-day 5) trihydrochloride inhibits the growth of MM.1S cells in a dose- and time-dependent manner. JQKD82 trihydrochloride is potent at eliciting growth suppression in MM.1S cells (IC50=0.42 μM)[1].JQKD82 (1 μM; 24 hours) trihydrochloride induces G1 cell-cycle arrest by 48 hours in MM.1S and MOLP-8 cells[1].
JQKD82 (50-75 mg/kg; i.p.; twice a day for 3 weeks) trihydrochloride has anti-multiple myeloma activity[1].JQKD82 trihydrochloride displays an increase in H3K4me3 levels and results in a dramatic reduction of MYC immuno-staining in vivo[1].
[1]. Jun Qi, et al. Histone demethylase 5 inhibitors and uses thereof. WO2020033377A1.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *